bioMérieux S.A. (BMXMF)
OTCMKTS · Delayed Price · Currency is USD
142.45
0.00 (0.00%)
Jul 15, 2025, 4:00 PM EDT
bioMérieux Revenue
In the year 2024, bioMérieux had annual revenue of 3.98B EUR with 8.31% growth. bioMérieux had revenue of 2.08B in the half year ending December 31, 2024, with 7.61% growth.
Revenue
3.98B EUR
Revenue Growth
+8.31%
P/S Ratio
3.93
Revenue / Employee
269.75K EUR
Employees
14,754
Market Cap
16.20B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
bioMérieux News
- 4 months ago - bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 months ago - bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 years ago - bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript - Seeking Alpha
- 4 years ago - bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript - Seeking Alpha
- 4 years ago - bioMérieux: Pioneering In Vitro Diagnostics - Seeking Alpha
- 4 years ago - bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha